MK-4280A-008

Phase 3 Randomized Clinical Study of MK-4280A (coformulated;favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus PhysicianÀs Choice;Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma;(KEYFORM-008).

Open at Saint-Cloud since : 29/08/2024
Target : Adult
Phase : Phase III

Trial description

To compare MK-4280A to physicianÀs;choice chemotherapy with respect to PFS;per Lugano response criteria by BICR;Hypothesis (H1): MK-4280A is superior to;physician's choice chemotherapy with;respect to PFS per Lugano response criteria;by BICR.

Url of the trial